Summary: “For those in the community seeking to develop drugs, run clinical trials, and interface with the regulatory sciences, does it make sense to consider a PBC (Public Benefit Corporation) option?” asks The Trip Report in an article exploring MAPS’ psychedelic drug development business model that maximizes public benefit over profit. The article highlights differences between organizations designated as for-profit, non-profit, and public benefit corporations, stating, “psychedelic medicine is uniquely positioned to point the way” towards ethical business models. MAPS Founder Rick Doblin, Ph.D., reminds us, “Public Benefit and even non-profit pharmaceutical development is already possible.”
Originally appearing here.
